In this episode of the Midweek Takeaway, we’re joined by Tim McCarthy, CEO, and Dr Sébastien Goudreau, newly appointed CSO of ImmuPharma. The company has just announced a groundbreaking patent for its lead asset P140, the world’s first “Immunormalizer,” offering a precision diagnostic and treatment approach for autoimmune diseases. With potential 20-year exclusivity, the patent targets patients with the newly identified “Type M” immune disorder, who are super-responders to P140, opening the door to safer, more effective therapies across up to 50 autoimmune conditions. We discuss how this dual opportunity as both a first-in-class therapy and novel diagnostic test positions ImmuPharma at the forefront of a $100bn treatment and $10bn diagnostics market, what this means for partnering potential, and why the company believes P140 could transform the landscape of autoimmune disease management.

This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.